conditions that are not characteristic of FH. In our study, treatment with both simvastatin and atorvastatin showed similar increases in fibrinogen levels. Theses increases were statistically significant but relatively small. Some previous studies, however, showed no changes in fibrinogen levels using simvastatin but did show a 40% increase using high-dose atorvastatin. These discrepancies might be partially explained by the dose or the duration of the treatment, by the baseline fibrinogen values, by the heterogenous nature of the patients recruited, or by the methods used to measure fibrinogen in the different studies.